ClinicalTrials.Veeva

Menu

Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh (BRAVOII)

T

Tela Bio

Status

Enrolling

Conditions

Hernia, Inguinal
Hernia, Ventral

Treatments

Device: OviTex Reinforced Tissue Matrix

Study type

Interventional

Funder types

Industry

Identifiers

NCT04779918
TB.2020.01.01

Details and patient eligibility

About

This study is designed to evaluate the post-operative complications and hernia recurrence following the use of OviTex in subjects with ventral or inguinal hernias. Up to 160 subjects will participate in the study from up to 20 investigator sites.

Full description

This study is intended to evaluate the post-operative complications and recurrence following the use of OviTex in ventral or inguinal hernias being treated robotically. It is a single-arm study and all subjects will receive OviTex.

Enrollment

160 estimated patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  1. Subject suffers from a ventral or inguinal hernia that requires surgical repair with the use of an implant to reinforce or replace weakened or missing tissue.
  2. The patient is scheduled for an elective robotic approach with the use of OviTex LPR, OviTex Core Permanent, or OviTex 1S Permanent.
  3. The size of the implant needed for repair is expected to be less than or equal to 15 x 25 cm for OviTex LPR and 25 x 40 cm for OviTex Core Permanent and OviTex 1S Permanent.
  4. Subject meets CDC/SSI Wound Classification Class I (Clean), Class II (Clean-Contaminated) or Class III (Contaminated) criteria.
  5. Subject is willing and able to sign an informed consent for the study and has signed the IRB approved Informed Consent form for this study.
  6. Subject is able to complete Quality of Life (QoL) and pain questionnaires.
  7. Subject is at least 21 years old.
  8. Subject is willing to comply and able to participate fully in, and for the full duration of, the study including follow-up requirements.

Exclusion Criteria at Baseline:

  1. Subject has a BMI of > 40
  2. Subject meets CDC/SSI Wound Classification Class IV (Dirty-Infected) criteria
  3. Subject is female and is pregnant or plans to become pregnant during the course of the study.
  4. Subject has a life expectancy of < 2 years making it unlikely that the subject will successfully achieve two-year follow-up.
  5. Subject has recent history of drug or alcohol abuse (in last 3 years).
  6. Subject has an allergy to ovine-derived products.
  7. Subject has participated in another clinical trial within the past 30 days or is currently involved in another clinical trial.
  8. Subject has a strangulated hernia.

Exclusion Criteria Intraoperative:

  1. Subject requires implant that cannot be introduced into the surgical site during the procedure via port or an existing incision.
  2. Subject unable to receive OviTex LPR, OviTex Core Permanent, or OviTex 1S Permanent time of surgery.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

160 participants in 1 patient group

OviTex Reinforced Tissue Matrix
Other group
Description:
This is a single-arm study. All study subjects will receive OviTex.
Treatment:
Device: OviTex Reinforced Tissue Matrix

Trial contacts and locations

8

Loading...

Central trial contact

Danielle Campbell; Melissa LaMantia

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems